Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Zacks · 6天前
Intersect ENT shares are trading higher after the company reported better-than-expected Q2 sales results.
Benzinga · 6天前
Intersect ENT EPS misses by $0.09, beats on revenue
Intersect ENT (NASDAQ:XENT): Q2 Non-GAAP EPS of -$0.65 misses by $0.09; GAAP EPS of -$0.71 misses by $0.13. Revenue of $9.78M (-63.3% Y/Y) beats by $1.91M.
seekingalpha · 08/04 16:06
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.56) by 16.07 percent. This is a 80.56 percent decrease over losses of $(0.36) per share from
Benzinga · 08/04 11:19
Intersect ENT Reports Second Quarter 2020 Financial Results
Intersect ENT Reports Second Quarter 2020 Financial Results
Business Wire · 08/04 11:00
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Did Hedge Funds Make The Right Call On Intersect ENT Inc (XENT) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which